Evidence map›Paper›PMID 35505019›Full record

ArticleMethods in molecular biology (Clifton, N.J.)2022

Photodynamic Treatments for Disseminated Cancer Metastases Using Fiber-Optic Technologies.

Eric M Kercher, Bryan Q Spring

Abstract read
PubMed Publisher
In one paragraph

Article in Methods in molecular biology (Clifton, N.J.), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Eric M KercherTranslational Biophotonics Cluster, Northeastern University, Boston, MA, USA.
Bryan Q SpringTranslational Biophotonics Cluster, Northeastern University, Boston, MA, USA. b.spring@northeastern.edu.

Funding

Online monitoring and image-guided treatment of chemoresistant micrometastasesK22CA181611 · NCI · NORTHEASTERN UNIVERSITY · PI SPRING, BRYAN QUILTY · 2015 to 2017
$559k
NCI NIH HHS K22 CA181611
6 · The paper itself

Abstract

Tumor-targeted and -activatable photosensitizer delivery platforms are creating new opportunities to develop photodynamic therapy (PDT) of metastatic disease. This is possible by confining the activity of the photosensitizing chemical (i.e., the PDT agent) to the tumor in combination with diffuse near-infrared light irradiation for wide-field treatment. This chapter outlines protocols and research tools for preclinical development of light-activated therapies of cancer metastases using advanced-stage ovarian cancer as a model system. We also describe an in vivo molecular imaging approach that uniquely enables tracking intraperitoneal micrometastatic burden and responses to treatment using fluorescence microendoscopy.

Indexed as

Ovarian NeoplasmsPhotochemotherapyCarcinoma, Ovarian EpithelialFemaleHumansInfrared RaysPhotosensitizing AgentsPhotosensitizing AgentsCancer metastasesFluorescence microendoscopyMolecular imagingMouse modelsOvarian cancerPeritoneal carcinomatosisPhotodynamic therapyPhotoimmunotherapyTargeted therapy

Identifiers

PMID35505019

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.